CIK: 0001744967 · Show all filings
Period: Q4 2018 (Next →)
Filing Date: Feb 14, 2019
Total Value ($000): $104,187 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | Allakos Inc | 458,366 | $23,959 | 23.0% | $52.27 | — | COM | 01671P100 |
| — | Intercept Pharmaceuticals Inc | 234,375 | $23,623 | 22.7% | $100.79 | — | COM | 45845P108 |
| — | Principia Biopharma Inc | 383,480 | $10,504 | 10.1% | $27.39 | — | COM | 74257L108 |
| — | Sutro BioPharma Inc | 1,125,576 | $10,153 | 9.7% | $9.02 | — | COM | 869367102 |
| — | Odonate Therapeutics Inc | 595,850 | $8,390 | 8.1% | $14.08 | — | COM | 676079106 |
| LQDA | Liquidia Technologies Inc | 378,420 | $8,197 | 7.9% | $23.38 | 0.0% | COM | 53635D202 |
| — | Syros Pharmaceuticals Inc | 1,059,938 | $5,904 | 5.7% | $5.57 | — | COM | 87184Q107 |
| KALV | KalVista Pharmaceuticals Inc | 150,000 | $2,963 | 2.8% | $20.10 | 0.0% | COM | 483497103 |
| — | Evelo Biosciences Inc | 227,529 | $2,960 | 2.8% | $13.01 | — | COM | 299734103 |
| — | Miragen Therapeutics Inc | 909,090 | $2,755 | 2.6% | $3.03 | — | COM | 60463E103 |
| — | Aravive Inc | 442,733 | $1,558 | 1.5% | $3.52 | — | COM | 03890D108 |
| — | Catabasis Pharmaceuticals Inc | 300,000 | $1,311 | 1.3% | $4.37 | — | COM | 14875P206 |
| UROV | Urovant Sciences Ltd | 157,480 | $1,038 | 1.0% | $6.59 | — | COM | G9381B108 |
| — | Millendo Therapeutics Inc | 45,101 | $359 | 0.3% | $7.96 | — | COM | 60040X103 |
| — | Surface Oncology Inc | 78,300 | $332 | 0.3% | $4.24 | — | COM | 86877M209 |
| — | Trillium Therapeutics Inc | 71,619 | $122 | 0.1% | $1.70 | — | COM | 89620X506 |
| — | Edge Therapeutics Inc | 183,332 | $59 | 0.1% | $0.32 | — | COM | 279870109 |